Apr. 14, 2015
Overcoming Challenges in Developing Antibody Drugs Against Immune Check Point Targets – An Interview with Dr. Jing Li, Vice President of Biologics Discovery
Perspectives
-
-
Jan. 24, 2018Scale-Out Biomanufacturing – A Paradigm Change to Scale-Up – Summary of Webinar provided by Dr. Jie Chen, Vice President of CMC Management -
Feb. 08, 2018Is Continuous Biomanufacturing a Good Fit for Your Process? – Continuous Biomanufacturing Implementation – Frequently Asked Questions -
Apr. 11, 2019Biologic Products DNA to IND Timeline in 9 Months – Yes it can be done! -
Aug. 28, 2019New Flexible Bispecific Antibody Format Demonstrates Improved Therapeutic Properties And Manufacturability -
Sep. 09, 2019Antibody Drug Conjugate (ADC) Development And Manufacturing Challenges And Solutions -
Apr. 20, 2020Fierce Pharma Virtual Series – Expert Panel Discussion Featuring Chris Chen
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?